

Renal Biopsy for Tumour Histopathology Reporting Guide



Family/Last name

Date of birth

Given name(s)

Patient identifiers

Date of request

Accession/Laboratory number

Elements in **black text** are REQUIRED. Elements in **grey text** are RECOMMENDED.

SPECIMEN LATERALITY (Note 1)

- Not specified
- Left
 - Unifocal
 - Multifocal
- Right
 - Unifocal
 - Multifocal

- Bilateral
 - Unifocal in both kidneys
 - Multifocal in one kidney
 - Multifocal in both kidneys

- Other eg horseshoe kidney

 - Unifocal
 - Multifocal

OPERATIVE PROCEDURE

- Core/needle biopsy

Number of cores

OR Number cannot be determined

Core id.	Length (in mm)

- Wedge biopsy

Number of wedges

Wedge id.	Max. Dimension (in mm)

- Other, specify

TUMOUR SITE(S) (Note 2)

- Upper pole Not provided
- Mid zone Cannot be assessed
- Lower pole
- Cortex
- Medulla
- Other, specify

HISTOLOGICAL TUMOUR TYPE** (Note 3)

(Value list from the World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs, Fourth edition (2016) classification of renal cell tumours and the International Society of Urological Pathology Vancouver classification of renal neoplasia)

****Occasionally more than one histologic type of carcinoma occurs within the same kidney specimen. Each tumour type should be separately recorded.**

- Non diagnostic, specify why

- Clear cell renal cell carcinoma
- Multilocular clear cell renal cell neoplasm of low malignant potential
- Papillary renal cell carcinoma
 - Type 1
 - Type 2
 - Oncocytic
 - NOS
- Chromophobe renal cell carcinoma
 - Hybrid oncocytic chromophobe tumour
- Oncocytic tumour
- Collecting duct carcinoma
- Renal medullary carcinoma
- MiT family translocation renal cell carcinoma
 - Xp11 translocation renal cell carcinoma
 - t(6;11) renal cell carcinoma
 - Other, specify

- Mucinous tubular and spindle cell carcinoma
- Tubulocystic renal cell carcinoma
- Acquired cystic disease associated renal cell carcinoma
- Clear cell papillary/tubulopapillary renal cell carcinoma
- Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma
- Succinate dehydrogenase (SDH) deficient renal carcinoma
- Renal cell carcinoma, unclassified
- Other, specify

HISTOLOGICAL TUMOUR GRADE - WHO/ISUP (Note 4)

- Not applicable
- Grade X - Cannot be assessed
- Grade 1 - Nucleoli absent or inconspicuous and basophilic at 400x magnification
- Grade 2 - Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification
- Grade 3 - Nucleoli conspicuous and eosinophilic at 100x magnification
- Grade 4 - Extreme nuclear pleomorphism and/or multi nuclear giant cells and/or rhabdoid and/or sarcomatoid differentiation

SARCOMATOID MORPHOLOGY (Note 5)

- Not identified
- Present

RHABDOID MORPHOLOGY (Note 6)

- Not identified
- Present

NECROSIS (Note 7)

- Not identified
- Present

LYMPHOVASCULAR INVASION (Note 8)

- Not identified
- Present

CO-EXISTING PATHOLOGY IN NON-NEOPLASTIC KIDNEY (Note 9)

- None identified
- Insufficient tissue for evaluation
- Glomerular disease

Specify type

- Tubulointerstitial disease

Specify type

- Vascular disease

Specify type

- Cyst(s)

Specify type

- Tubular (papillary) adenoma(s)

- Other

Specify

ANCILLARY STUDIES (Note 10)

- Not performed
- Performed

Specify test and results

Scope

This dataset has been developed for core or wedge biopsy specimens for neoplasms of renal tubular origin. Non-epithelial tumours should be reported according to established guidelines.¹ Excision specimens are not included – a separate dataset is available and should be used for these cases.

Note 1 – Specimen laterality (Required)

Reason/Evidentiary Support

Specimen laterality information is needed for identification and patient safety purposes.

Core biopsy from two different tumours is fairly uncommon. This may occur in presumed von Hippel Lindau syndrome patients. If, for example, more than 1 tumour is being monitored for growth rate, both may be sampled as part of the same procedure.

[↑ Back](#)

Note 2 – Tumour site(s) (Recommended)

Reason/Evidentiary Support

The position of the tumour in relation to the renal cortex or medulla may also have diagnostic importance. This is especially important for small tumours where a site of origin within the medulla would support a diagnosis of collecting duct carcinoma or medullary carcinoma.¹

[↑ Back](#)

Note 3 - Histological tumour type (Required)

Reason/Evidentiary Support

Many of the various sub-types of renal epithelial neoplasia exhibit differing clinical behaviour and prognosis.^{1,2,9-14} This has been confirmed in large single and multicentre studies for the main tumour sub-types. Several series have also clearly demonstrated that many of the newly described entities of renal malignancy have a prognosis that differs from that of clear cell renal cell carcinoma.¹⁴ In addition to this protocols for the various types of adjuvant anti-angiogenic therapy relate to specific tumour sub-types.¹⁵

The 2013 International Society of Urological Pathology (ISUP) Vancouver Classification of adult renal tumours identified an emerging/provisional category of renal cell carcinoma (RCC).⁸ While appearing distinctive, these rare tumours had not been fully characterized by morphology, immunohistochemistry and molecular studies. This category was also included in the fourth edition of the World Health Organisation (WHO) classification of renal neoplasia. In the WHO classification oncocytoid RCC post-neuroblastoma, thyroid-like follicular RCC, anaplastic lymphoma kinase (ALK) rearrangement-associated RCC and RCC with (angio) leiomyomatous stroma are included in this category. These entities should be classified under 'other' with the name specified.

Papillary RCC has traditionally been subdivided into Type 1 and Type 2.¹⁶ Recent studies have shown these tumours to be clinically and biologically distinct. Type 1 tumours are associated with alterations in the MET pathway while type 2 tumours are associated with activation of the NRF2-ARE pathway. On the basis of molecular features type 2 tumours may be sub-divided into at least 3 subtypes.¹⁷ Type 1 and type 2 tumours show differing immunohistochemical staining with type 1 tumours more frequently expressing cytokeratin 7 in comparison to type 2.^{1,8,16,17}

Oncocytic papillary renal cell carcinoma is a category included in the fourth edition of the WHO renal tumour classification.¹ While not fully characterized, this tumour is best included in the broader papillary category.

Papillary RCC is associated with a more favourable outcome than clear cell renal cell carcinoma (ccRCC), collecting duct carcinoma and hereditary leiomyomatosis and renal cell carcinoma (HLRCC)^{1,14} Papillary subtyping is also of prognostic significance with type 1 tumours having a more favourable prognosis than those with type 2 morphology.^{14,16,17}

On occasion it may be difficult to accurately classify tumours with deeply eosinophilic cytoplasm on renal biopsy. Here the differential diagnosis includes oncocytoma, chromophobe renal cell carcinoma, oncocytic papillary renal cell carcinoma and post-neuroblastoma renal cell carcinoma. Immunohistochemical assessment may be helpful but due to the limited tissue available in a needle biopsy this may be inconclusive. In such instances the term oncocytic neoplasm may be used with a note emphasising that this is not a diagnostic category but a descriptor that includes both benign and malignant entities.^{18,19}

The benign entities of renal neoplasia commonly encountered in renal biopsies such as oncocytoma, angiomyolipoma, papillary adenoma, metanephric adenoma and other forms of adenoma should be classified under 'other' with the diagnosis specified.

[↑ Back](#)

Note 4 – Histological tumour grade – WHO/ISUP (Required)

Reason/Evidentiary Support

Grade should be assigned based on the single high power field showing the greatest degree of nuclear pleomorphism.

This grading system is the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) grading system for renal cell carcinoma which is recommended in the 2016 WHO.^{1,14} This system has been validated as a prognostic parameter for clear cell and papillary renal cell carcinoma.^{14,20,21} It has not been validated for other types of renal cell carcinoma but may be used for descriptive purposes.²² The current recommendation is that chromophobe renal cell carcinoma is not graded.^{1,23}

There is debate regarding the validity of grading renal cell neoplasms in needle biopsies because of the likelihood that the tissue sampled may not be representative. This is of particular concern in large renal neoplasms where there can be considerable morphologic variability. In some series it is recommended that tumours in renal core biopsies not be graded. If a grade is given it should be qualified with a note stating that the provided grade may underestimate the true grade of the tumour.^{18,19}

[↑ Back](#)

Note 5 - Sarcomatoid morphology (Required)

Reason/Evidentiary Support

The presence of sarcomatoid morphology is seen in approximately 5% of renal cell carcinomas and is associated with a poor prognosis.^{14,24-27} Numerous studies have confirmed that sarcomatoid morphology may occur within any of the main subtypes of renal cell carcinoma and represents high grade disease.^{1,8} The five year survival for patients with sarcomatoid morphology is of the order of 15 to 22%.^{1,8,24-27} The outcome associated with sarcomatoid morphology is stage dependent.²⁸ The presence of sarcomatoid morphology is incorporated into the WHO/ISUP grading system (Grade 4).¹⁴

[↑ Back](#)

Note 6 - Rhabdoid morphology (Required)

Reason/Evidentiary Support

Similar to the sarcomatoid morphology, rhabdoid morphology is a feature of high grade disease.^{14,29} Tumours showing this phenotype resemble rhabdoid cells having bulky eosinophilic cytoplasm and an eccentric nucleus, often with a prominent nucleolus.^{1,8} Rhabdoid change is associated with a poor prognosis. It has been shown that 71% of patients with rhabdoid morphology developed metastases with a mean follow-up of 4.5 months. Within 2 years it was also noted that 43% of patients in this series had died, with a median survival rate of 8-31months.^{14,29-31} In approximately 25% of tumours with rhabdoid morphology, there is co-existing sarcomatoid carcinoma.¹ The presence of rhabdoid morphology is incorporated into the WHO/ISUP grading system (Grade 4).¹⁴

↑ Back

Note 7 - Necrosis (Required)

Reason/Evidentiary Support

The presence of tumour necrosis has been shown to be a prognostic indicator for clear cell renal cell carcinoma and chromophobe renal cell carcinoma independent of tumour stage.^{14,37} Papillary renal cell carcinoma typically contains foci of necrosis, however the prognostic significance of this is, at best debated. At present it is recommended that the presence of macroscopic (confluent) and microscopic (coagulative) necrosis be recorded.¹⁴

↑ Back

Note 8 – Lymphovascular invasion (Required)

Reason/Evidentiary Support

Microvascular invasion has been shown to correlate with the development of metastases and with survival, independent of tumour size, primary tumour category, and grade.⁴²

In both clear cell and papillary RCC, tumour spread is predominantly haematogenously via the sinus veins, renal vein and vena cava to the lung. Infiltration of the perirenal fat can result in retroperitoneal spread. Lymphatic spread to the nodes of the renal hilum may also occur and is more common in papillary RCC than with ccRCC.²

↑ Back

Note 9 – Co-existing pathology in non-neoplastic kidney (Required)

Reason/Evidentiary Support

It is important to recognize that medical kidney diseases may be present in nonneoplastic renal tissue in nephrectomy and nephroureterectomy specimens.^{1,2} Arterionephrosclerosis (or hypertensive nephropathy) and diabetic nephropathy are seen in approximately 30% and 20% of cases, respectively. Other medical renal diseases that have been identified include thrombotic microangiopathy, focal segmental glomerulosclerosis, and IgA nephropathy. The findings of greater than 20% global glomerulosclerosis or advanced diffuse diabetic glomerulosclerosis are predictive of significant decline in renal function 6 months after radical nephrectomy.² Evaluation for medical renal disease should be performed in each case; PAS and/or Jones methenamine silver stains should applied if necessary. Consultation with a nephropathologist should be pursued as needed.

For the assessment of co-existing pathology in renal tissue adjacent to tumour the local effects of an expansile and/or infiltrative neoplasm should be considered. This may be associated with an appreciable degree of inflammation and scarring, and it is not uncommon to see localized secondary interstitial nephritis, glomerulosclerosis and tubular atrophy.

↑ Back

Note 10 – Ancillary studies (Recommended)

Reason/Evidentiary Support

Ancillary studies are being increasingly utilized for subtyping of renal cell neoplasms. Fluorescent in-situ hybridization (FISH) can be used to confirm a diagnosis of translocation carcinoma (MiT family tumour) and has been shown to be of utility in distinguishing oncocytoma from chromophobe renal cell carcinoma.¹ Cytogenetics may be undertaken in some instances; however, this is not usually performed as part of the routine assessment of a renal tumour. It is now recognized that Immunohistochemical assessment of tumours can be diagnostically helpful. There are currently no ancillary tests that are accepted as having prognostic significance for renal cell neoplasms.^{43,44}

↑ Back

References

1. World Health Organization (WHO) Classification of tumours. Pathology and genetics of the urinary system and male genital organs. Humphrey PA, Moch H, Reuter VE, Ulbright TM, editors. Lyon, France: IARC Press. 2016
2. Amin MB, Edge SB, Greene FL, *et al*, eds. (2017) AJCC Cancer Staging Manual. 8th ed. New York: Springer
3. Delahunt B, Kittelson JM, McCredie MRE, *et al*. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma. Assessment of TNM T1 and T2 categories and comparison with other prognostic parameters. *Cancer* 2002; 94: 658-664
4. Störkel S, Eble JN, Adlakha K, *et al*. Classification of renal cell carcinoma. *Cancer* 1997;80:987-989.
5. Bonsib SM, Gibson D, Mhoon M, Greene GF. Renal sinus involvement in renal cell carcinoma. *Am J Surg Pathol* 2000; 24: 451-458.
6. Bonsib SM. T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. *J Urol* 2005; 174: 1199-1202.
7. Thompson RH, Leibovich BC, Cheville JC *et al*. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? *J Urol* 2005; 174: 1218-1221.
8. Srigley JR, Delahunt B, Eble JN, *et al*. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol* 2013; 37: 1469-1489.
9. Murphy WM, Grignon DJ, Perlman EJ, editors. Tumours of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumour Pathology Series 4. American Registry of Pathology. Washington DC; 2004.
10. Kim H, Cho NH, Kim D *et al*. Renal cell carcinoma in South Korea: A multicenter study. *Hum Pathol* 2004; 35: 1556-1563.
11. Ljungberg B, Alamdri FI, Stenling R *et al*. Prognostic significance of the Heidelberg Classification of renal cell carcinoma. *Eur Urol* 1999; 36: 565-569.

12. Moch H, Grasser T, Amin MB. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. A Swiss experience with 588 tumours. *Cancer* 2000;89:604-614.
13. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. *Modern Pathology* 2009;22:S2-S23.
14. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. 2013; 37:1490-1504.
15. O'Brien MF, Russo P, Motzer RJ. Sunitinib therapy in renal cell carcinoma. *BJU International* 2008;101:1339-1342.
16. Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. *Hum Pathol* 2002; 32: 590-595.
17. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. *NEJM* 2015; 1-10. November 4, 2015DOI: 10.1056/NEJMoa1505917
18. Delahunt B, Samaratunga H, Martignoni G, Srigley JR, Evans AJ, Brunelli M. Percutaneous renal tumour biopsy. *Histopathology* 2014; 65: 295-308.
19. Evans AJ, Delahunt B, Srigley JR. Issues and challenges associated with classifying neoplasms in percutaneous needle biopsies of incidentally found small renal masses. *Semin Diagn Pathol* 2015; 32: 184-195.
20. Sika-Paotonu D, Bethwaite PB, McCredie MRE, Jordan TW, Delahunt B. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. *Am J Surg Pathol* 2006; 30: 1091-1096.
21. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. *Am J Surg Pathol* 2011; 135: 1134-1139.
22. Delahunt B, Egevad L, Samaratunga H, et al. Gleason and Fuhrman no longer make the grade. *Histopathology*. 2016 Mar;68(4):475-81.
23. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. *Am J Surg Pathol* 2007; 31: 957-960.
24. Cheville JC, Lohse CM, Zincke H et al. Sarcomatoid renal cell carcinoma. An examination of underlying histologic subtype and an analysis of associations with patient outcome. *Am J Surg Pathol* 2004;28:435-441.
25. Cangiano T, Liao J, Naitoh J et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis and response to combined surgical resection and immunotherapy. *J Clin Oncol* 1999;17:523-528.
26. Delahunt B. Sarcomatoid renal cell carcinoma. the final common dedifferentiation pathway of renal epithelial malignancies. *Pathology* 1999; 31: 185-190.
27. de Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma. A study of 101 cases. *Am J Surg Pathol* 2001; 25: 275-278.
28. Mian BM, Bhadkamkar N, Slaton JW et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. *J Urol* 2002; 167: 64-70.
29. Kuroiwa K, Kinoshita Y, Shiratsuchi H et al. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm. *Histopathology* 2002; 41: 538-548.
30. Gokden N, Nappi O, Swanson PE et al. Renal cell carcinoma with rhabdoid features. *Am J Surg Pathol* 2000; 24: 1329-1338.
31. Leroy X, Zini L, Buob D et al. Renal cell carcinoma with rhabdoid features. *Arch Pathol Lab Med* 2007; 131: 102-106.

32. Trpkov K, Grignon DJ, Bonsib SN et al. Handling and staging of renal cell carcinoma. The International Society of Urological Pathology (ISUP) consensus conference recommendations. *Am J Surg Pathol* 2013; 37: 1505-1517.
33. Bonsib SM. Renal lymphatics, and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a study of 40 cases. *Mod Pathol* 2006; 19 :746-753.
34. Madbouly K, Al-Qahtani SM, Ghazwani Y et al. Microvascular tumour invasion: prognostic significance in low stage renal cell carcinoma. *Urology* 2007; 69: 670-674.
35. Thompson RH, Cheville JC, Lohse CM et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. *Cancer* 2005; 104: 53-60.
36. Ficcaro V, Novara G, Iafrate M et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. *Eur Urol* 2007; 51: 722-729.
37. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparison of outcome and prognostic features among histologic subtypes of renal cell carcinoma. *Am J Surg Pathol* 2003; 27: 612-624.
38. Klatte T, Said JW, de Martino M et al. Presence of tumour necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. *J Urol* 2009; 181: 1558-1564.
39. Terrone C, Cracco C, Porpiglia et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. *Eur Urol* 2006; 49: 324-331.
40. Henriksen KJ, Meehan SM, Chang A. Non-neoplastic renal diseases are often unrecognized in adult tumor nephrectomy specimens: a review of 246 cases. *Am J Surg Pathol* 2007; 31:1703-1708.
41. Bijol V, Mendez GP, Hurwitz S, Rennke HG, Nose V. Evaluation of the non-neoplastic pathology in tumor nephrectomy specimens: predicting the risk of progressive failure. *Am J Surg Pathol* 2006; 30: 575-584.
42. Lang H, Lindner V, Letourneux H et al. Prognostic value of microscopic venous invasion in renal cell carcinoma: long term follow-up. *Eur Urol* 2004; 46: 331-335.
43. Tan P-H, Cheng L, Leclercq-Roux N, Merino M, Netto G, Reuter V, Shen S, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H, The ISUP Renal Tumor Panel. Renal cancer biomarkers: Diagnosis and prognosis. *Am J Surg Pathol* 2013; 37: 1518-1531.
44. Reuter VE, Argani P, Zhou M, Delahunt b, Amin MB, Epstein JI, Ulbright TM, Humphrey PA, Egevad L, Montironi R, Grignon D, Trpkov K, Lopez-Beltran A, Berney DM, Srigley JR. Best practice recommendations in the application of immunohistochemistry in kidney tumors.; report for the International society of Urological Pathology consensus conference. *Am J Surg Pathol* 2014; 38: e35-e49.